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ABSTRACT
Objectives: For healthy women at high risk of
developing breast cancer, a bilateral mastectomy can
reduce future risk. For women who already have
unilateral breast cancer, removing the contralateral
healthy breast is more difficult to justify. We examined
trends in the number of women who had a bilateral
mastectomy in England between 2002 and 2011.
Design: Retrospective cohort study using the Hospital
Episode Statistics database.
Setting: NHS hospital trusts in England.
Participants: Women aged between 18 and 80 years
who had a bilateral mastectomy (or a contralateral
mastectomy within 24 months of unilateral
mastectomy) with or without a diagnosis of breast
cancer.
Main outcome measures: Number and incidence of
women without breast cancer who had a bilateral
mastectomy; number and proportion who had a
bilateral mastectomy as their first breast cancer
operation, and the proportion of those undergoing
bilateral mastectomy who had immediate breast
reconstruction.
Results: Among women without breast cancer, the
number who had a bilateral mastectomy increased
from 71 in 2002 to 255 in 2011 (annual incidence rate
ratio 1.16, 95% CI 1.13 to 1.18). In women with breast
cancer, the number rose from 529 to 931, an increase
from 2% to 3.1% of first operations (OR for annual
increase 1.07, 95% CI 1.05 to 1.08). Across both
groups, rates of immediate breast reconstruction
roughly doubled and reached 90% among women
without breast cancer in 2011.
Conclusions: The number of women who had a
bilateral mastectomy nearly doubled over the last
decade, and more than tripled among women without
breast cancer. This coincided with an increase in the
use of immediate breast reconstruction.
INTRODUCTION
There are two distinct groups of women who
undergo bilateral mastectomy (BM): those
without breast cancer but with familial breast
cancer or known genetic mutations (BRCA1
or BRCA2) and those with breast cancer in
one or both breasts. Guidelines produced by
the UK National Institute for Health and
Clinical Excellence (NICE) state that
ARTICLE SUMMARY
Article focus
▪ National Institute for Health and Clinical
Excellence (NICE) guidelines in England support
the use of bilateral mastectomy among healthy
women with a high risk of developing breast
cancer.
▪ In the USA, bilateral mastectomy among women
with unilateral breast cancer has become more
common but evidence of improved survival is
weak.
▪ We examined trends in use of bilateral mastec-
tomy in English National Health Service (NHS)
hospitals among women with and without breast
cancer between 2002 and 2011.
Key messages
▪ In 2002, 71 women without breast cancer had a
bilateral mastectomy. By 2011, this had
increased to 255 women.
▪ Among women with breast cancer who had sur-
gical treatment, the proportion that had a bilat-
eral mastectomy rose from 2.0% in 2002 to
3.1%.
▪ The proportion of women who had immediate
breast reconstruction also increased for both
groups of women over this period.
Strengths and limitations of this study
▪ The strength of this study comes from using a
national administrative database of all NHS hos-
pital admissions in which we could identify
women having a mastectomy and procedure
laterality.
▪ The database does not distinguish unilateral
from bilateral breast cancer, so we were could
not exclude women who had a therapeutic bilat-
eral mastectomy.
Neuburger J, MacNeill F, Jeevan R, et al. BMJ Open 2013;3:e003179. doi:10.1136/bmjopen-2013-003179 1
Open Access Research
 group.bmj.com on August 6, 2013 - Published by bmjopen.bmj.comDownloaded from 
risk-reducing BM may be appropriate for high-risk
women without breast cancer. High-risk is deﬁned as a
lifetime risk of 30% or higher, compared with an
average risk of 11% in the UK women.1 This advice is
consistent with clinical evidence that removal of both
healthy (non-cancerous) breasts can reduce the future
incidence of breast cancer in high-risk women.2–5
Some women with unilateral breast cancer have the
healthy breast removed to reduce their risk of contralat-
eral breast cancer. Both breasts can be removed simul-
taneously or the contralateral healthy breast can be
removed at a later date. Although the contralateral mast-
ectomy may reduce the risk of developing a future
malignant breast tumour and the need for further
breast cancer treatments, a 2010 Cochrane Review found
insufﬁcient evidence of improved survival.5
Over the last two decades in the USA the use of
contralateral risk-reducing mastectomy has increased,
from 1–2% to around 5% of women having breast
cancer surgery.6–9 Several reasons have been suggested
for this increase, including wider availability of genetic
testing, avoidance of long-term breast surveillance and
increased availability of immediate breast reconstruction.
Patients and health professionals may also overestimate
the risk of contralateral breast cancer.10 However, trends
in the UK and rest of Europe may be different as a
result of different medical and cultural attitudes toward
extensive ablative surgery and aesthetic surgery.11
Our aim was to investigate trends in bilateral mastec-
tomy for women without and with a breast cancer diag-
nosis in England between 2002 and 2011. We also
examined trends in immediate breast reconstruction to
assess the role that this might have played.
METHODS
Data definitions and selection of cohort
We used data extracted from the Hospital Episode
Statistics (HES) database,12 which covers all admissions
to English National Health Service (NHS) hospital
trusts. A unique patient identiﬁer allows same patient
admissions to be linked. Each HES record captures up
to 24 procedures, using the UK Ofﬁce of Population
Censuses and Surveys (OPCS) classiﬁcation, V.4.4.
Diagnoses are recorded using the International
Classiﬁcation of Diseases, 10th Revisions (ICD-10). Our
extract from HES covered the period from 2002 to 2011,
using ﬁnancial years (1 April to 31 March).
Bilateral mastectomy performed as a single operation
was identiﬁed by the OPCS codes B27 (mastectomy)
and Z94.1 (bilateral). Unilateral mastectomy was identi-
ﬁed by the code B27 in addition to Z94.2 (right sided),
Z94.3 (left sided) or Z94.4 (unilateral). We excluded
women with missing information on laterality. Because
high rates of missing information were concentrated in
4 of 162 NHS trusts, we re-ran our analyses after exclud-
ing these NHS trusts to check the robustness of the esti-
mated trends. Breast-conserving operations were
identiﬁed by the OPCS codes B28.1, B28.2, B28.3, B28.8
and B28.9.
Breast reconstruction was identiﬁed using OPCS codes
B29 (breast reconstruction, excluding B29.5 revision),
B38 (reconstruction using buttock ﬂap), B39 (recon-
struction using abdominal ﬂap), B30.1 (insertion of
prosthesis) and S48.2 (insertion of skin expander).
We identiﬁed women with breast cancer using the
ICD-10 diagnosis codes C50 (malignant neoplasm) and
D05 (carcinoma-in situ). The ICD-10 codes do not dis-
tinguish bilateral from unilateral breast cancer so it was
not possible to identify how many women had a thera-
peutic BM for bilateral breast cancer. The number of
women diagnosed with synchronous bilateral breast
cancer is thought to be extremely small and relatively
stable since the 1980 s, based on Swedish Cancer
Register data and studies from Australasia and the
Netherlands.13–16
We selected women aged 18–80 years who fulﬁlled
one of the following two inclusion criteria: (1) they had
a BM between 2002 and 2011 or (2) they had a ﬁrst
breast cancer operation between 2002 and 2011 and had
a current or previous diagnosis of breast cancer. A previ-
ous diagnosis of breast cancer was determined by check-
ing women’s HES records going back to April 2000.
From this cohort, we distinguished between two
groups of women who underwent BM. The ﬁrst group
comprised of women who did not have a current or pre-
vious diagnosis of breast cancer. All women in this group
had BM as a simultaneous procedure.
The second group included women who had a
current or previous diagnosis of breast cancer. Women
in this group underwent simultaneous BM or had a
contralateral mastectomy as a separate procedure within
24 months of the unilateral mastectomy. This approach
is referred to in this paper as two procedure BM.
Removal of a contralateral breast may be decided at the
time of the initial cancer diagnosis but only be per-
formed after completion of adjuvant therapies (chemo-
therapy or in particular radiotherapy). Alternatively, the
decision for contralateral mastectomy may be made after
genetic assessment/testing and appropriate counselling,
during or after any adjuvant treatments.
Statistical analysis
We calculated the number of women who underwent
BM each ﬁnancial year from 2002 to 2011. Of the
women without breast cancer we identiﬁed, all were
aged between 25 and 69 years. We therefore calculated
the incidence of BM per 100 000 women in the English
population aged 25–69 as a denominator, using ﬁgures
published by the Ofﬁce for National Statistics.17 We then
used Poisson regression to estimate an annual trend in
the use of BM, including year as a linear term.
Among women with breast cancer, we calculated the
BM rate as a proportion out of all the ﬁrst breast cancer
operations undertaken that year. We used multivariable
logistic regression to estimate the annual trend in the
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proportion undergoing BM, including year as a linear
term, with and without adjusting for age. We report
average trends for the period 2002–2009. This is because
the number of two procedure BMs is underestimated for
2010 and 2011 because our extract from the HES data-
base extended only up to 31 March 2012, allowing
24 months of follow-up only for women who had a mast-
ectomy before 1 March 2010.
We calculated the percentage of women who under-
went immediate breast reconstruction following BM
each year, along with the 95% CIs.
In all cases, we tested for a change in trends using spline
terms, but only describe linear trends for simplicity of pres-
entation. Reported p values are based on likelihood ratio
tests. All analyses were carried out in Stata V.11.
RESULTS
Bilateral mastectomy in women without breast cancer
Between 2002 and 2011, the number of women without
breast cancer who underwent simultaneous BM
increased from 71 to 255 (table 1). The population inci-
dence increased from 0.4 to 1.3/100 000 women aged
25–69 years with an estimated annual increase of around
16% (incidence rate ratio 1.16, 95% CI 1.13 to 1.18,
p<0.001), although increases were smaller in recent
years (p<0.001).
Women without breast cancer comprised an increasing
fraction of all women undergoing BM, from 11.8% (71/
(71+529)) in 2002 to 19.9% in 2009 (232/(232+931);
tables 1 and 2). The average age at surgery was 40 years
and did not change over this time period.
Bilateral mastectomy in women with breast cancer
Between 2002 and 2009, the number of women with
breast cancer who underwent BM increased from 521 to
931, representing an increase from 2.0% to 3.1% of all
women undergoing their ﬁrst breast cancer operation
(table 2). The estimated annual increase was around 7%
(OR 1.07, 95% CI 1.05 to 1.08, p<0.001), with no strong
evidence of a change in trends over the period.
The average age at ﬁrst breast cancer operation was
58 years, for two procedure BM it was 51 years and for
simultaneous BM it fell from 57 to 54 years during the
study period.
Around two-ﬁfths of BMs were carried out as two pro-
cedures, with the contralateral mastectomy being per-
formed within 24 months.
Table 1 Number of women without breast cancer who had a bilateral mastectomy (BM) in England, 2002–2011
Number of women
who had a BM
Incidence per 100 000
women aged 25–69
Annual trend
IRR (95% CI) p Value
2002 71 0.4 1.16 (1.13 to 1.18) <0.001
2003 72 0.4
2004 101 0.6
2005 131 0.7
2006 147 0.8
2007 201 1.1
2008 186 1.0
2009 232 1.2
2010 238 1.3
2011 255 –
Table 2 Number (%) who had a bilateral mastectomy (BM) out of women with breast cancer having their first operation,
2002–2011
All women who
had first breast
cancer operation
No of women who had a BM Annual trend (2002–2009)
Performed as
same operation
Performed as
two operations Total (%) OR (95% CI) p Value
2002 25 844 308 221 529 (2.0) 1.07 (1.05 to 1.08) <0.001
2003 27 303 332 263 595 (2.2)
2004 27 643 335 269 604 (2.2)
2005 29 179 369 312 681 (2.3)
2006 28 645 407 307 714 (2.5)
2007 28 702 432 336 768 (2.7)
2008 29 629 493 384 877 (3.0)
2009 29 745 546 385 931 (3.1)
2010 30 760 528 263* –
2011 31 240 617 93* –
*These figures are incomplete since our version of the HES database only covers the period up to 31 March 2012.
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Rates of immediate breast reconstruction 2002–2011
Among women without breast cancer, the immediate
breast reconstruction rate increased substantially from
59.2% (95% CI 46.8% to 70.7%) to 90.6% (95% CI
86.3% to 93.9%; table 3). Reconstruction rates were
higher among younger women, particularly those under
40 years (p<0.001).
Among women with breast cancer who had simultan-
eous BM, the immediate breast reconstruction rate
increased from 18.2% (95% CI 14.0% to 23.0%) to
40.8% (95% CI 36.9% to 44.8%). The immediate recon-
struction rate among women who underwent BM in two
procedures increased from 27.1% (95% CI 21.4% to
33.5%) to 53.8% (95% CI 43.1% to 64.2%).
DISCUSSION
Summary of results
Over the past decade the total number of women in
England who had a bilateral mastectomy nearly doubled,
from around 600 to 1000 women/year. Proportionally,
the largest increase in BM incidence was seen in women
without breast cancer. Their number tripled from 71 to
255 between 2002 and 2009, representing an increase in
uptake among women aged 25–69.
Overall, the majority of women who underwent BM
had breast cancer. In this group there was an increase in
the number who underwent BM (in one or two proce-
dures) between 2002 and 2009, representing a modest
increase from around 2% to 3% of women undergoing
their ﬁrst breast cancer operation.
Between 2002 and 2011, rates of immediate breast
reconstruction after BM roughly doubled to nearly 50%
for women with cancer and over 90% for women who
did not have breast cancer.
Strengths and limitations of the study
The comprehensiveness of HES enabled us to identify
different hospital admissions for the same woman over a
long period of time. Because HES links separate epi-
sodes of care for the same patient, we could reliably
identify contralateral mastectomies performed within
24 months of a ﬁrst unilateral mastectomy.
The main limitation of HES is the lack of codes indicat-
ing whether a breast cancer diagnosis is unilateral or
bilateral. This meant that we were unable to exclude
from our analysis women with bilateral breast cancer at
initial diagnosis, or diagnosed with an occult or new
contralateral breast cancer within 24 months of the index
cancer. As a result, among women with breast cancer,
those who underwent a therapeutic BM are included in
our ﬁgures. Of women diagnosed with breast cancer in
the Swedish Cancer Register, around 1% of women were
ﬁrst diagnosed with bilateral breast cancer and less than
half a per cent were diagnosed with contralateral breast
cancer within 24 months of a ﬁrst diagnosis,13 and these
rates have remained stable or decreased since the
1980s.14 Two recent population-based studies from
Australasia and the Netherlands reported comparable
bilateral breast cancer rates of 2.3% and 2.2%, respect-
ively.15 16 Assuming trends in the UK are comparable, it is
unlikely that a change in incidence alone could explain
the observed increase in BM rates. Increased detection of
bilateral breast cancers through the NHS Breast
Screening Programme is also unlikely to explain the
increase in BM rates, since we found higher rates and
larger increases in rates among women aged under
50 years, who would not have been routinely screened
over the study period. Improved MRI detection of occult
contralateral breast cancers could have contributed to
the increase in the rate of contralateral mastectomy fol-
lowing a unilateral mastectomy.18 However, on checking
the use of codes for prophylactic surgery within our data-
base, we were able to conﬁrm that, at a minimum, half of
these procedures were intended as risk-reducing opera-
tions and more than 60% since 2009.
A further limitation of HES, common to administrative
databases, is the potential for inaccuracies and omissions
Table 3 Number (%) of women who underwent immediate breast reconstruction of those who had a bilateral mastectomy
(BM), by presence of a breast cancer diagnosis, 2002–2011
Women without breast
cancer Women with breast cancer
BM in same operation BM in two operations
No % (95% CI) No % (95% CI) No % (95% CI)
2002 42 59.2 (46.8 to 70.7) 56 18.2 (14.0 to 23.0) 60 27.1 (21.4 to 33.5)
2003 47 65.2 (53.1 to 76.1) 43 13.0 (9.5 to 17.0) 80 30.4 (24.9 to 36.3)
2004 70 69.3 (59.3 to 78.1) 58 17.3 (13.4 to 21.8) 83 30.9 (25.4 to 36.7)
2005 87 66.4 (57.6 to 74.4) 80 21.7 (17.6 to 26.2) 105 33.7 (28.4 to 39.2)
2006 106 72.1 (64.1 to 79.2) 93 22.9 (18.9 to 27.2) 142 46.3 (40.6 to 52.0)
2007 160 79.6 (73.4 to 84.9) 103 23.8 (19.9 to 28.1) 155 46.1 (40.7 to 51.6)
2008 151 81.2 (74.8 to 86.5) 135 27.4 (23.5 to 31.5) 173 45.1 (40.0 to 57.3)
2009 203 87.5 (82.5 to 91.5) 185 33.9 (30.0 to 38.0) 201 52.2 (47.1 to 57.3)
2010 207 87.0 (82.0 to 91.0) 188 35.6 (31.5 to 40.0) 132* 50.2 (44.0 to 56.4)
2011 231 90.6 (86.3 to 93.9) 252 40.8 (36.9 to 44.8) 50* 53.8 (43.1 to 64.2)
*These figures are incomplete since our version of the HES database only covers the period up to 31 March 2012.
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in coding.19 Validation work carried out for breast cancer
surgery suggests that procedure codes in HES are accur-
ate, 90–93% agreement with data provided by surgeons.20
We carried out a separate analysis to check the impact of
missing procedure codes that indicated whether a mastec-
tomy was bilateral, right-sided or left-sided. The rate of
missing laterality codes decreased over the study period
from around 5.6% to 1.4% of ﬁrst mastectomies among
women with breast cancer. However, underuse of these
codes was concentrated in four NHS trusts, so we
re-estimated trends after excluding these trusts from our
analysis and were able to conﬁrm that the observed
increase in the rate of BM was similar that is, an increase
from 2% to 3% among women with breast cancer.
Ideally, to estimate changes in BM use among women
without breast cancer, the denominator would be the
number of women at a high risk of developing breast
cancer. Based on a single study, NICE estimated that up
to 2500 women aged 30–49 years in England and Wales
could be identiﬁed each year as having a genetic risk of
breast cancer,21 but actual numbers are not published.
By looking at rates of immediate breast reconstruction,
we have underestimated the total number of women with
breast cancer who underwent breast reconstruction
because many women undergo delayed reconstruction fol-
lowing their mastectomy.22 Delayed reconstruction may be
recommended when postmastectomy radiotherapy is
anticipated, since this can impair the long-term aesthetic
results of breast reconstruction.
Comparison with bilateral mastectomy trends in the USA
The dramatic increase in BM among women without
breast cancer in England has not been noted in the
USA over the past two decades, although an increase
could have occurred earlier in the USA.6 In contrast,
several US studies have identiﬁed an increase in contra-
lateral risk-reducing mastectomy among women with
breast cancer.6–9 Although the deﬁnitions and popula-
tions studied are not exactly the same as ours, the evi-
dence points toward a larger increase in risk-reducing
contralateral mastectomy in the USA than in England.
Various reasons have been suggested for the increase
in contralateral risk-reducing mastectomy in the USA.
One reason may be increased awareness of hereditary
risk and the associated use of genetic testing. Additional
drivers may be higher screening recall rates and the
need for additional breast assessment arising from
annual surveillance mammography and MRI undertaken
routinely in the USA.23
Reﬁnements of mastectomy techniques (skin-sparing
and nipple-sparing) and increased access to breast
reconstruction may also have contributed to the increase
of contralateral mastectomy. Higher immediate breast
reconstruction rates in the USA (up to 40% in 2008
compared with around 20% in the UK) may also partly
account for the relatively greater increase in contralat-
eral risk-reducing mastectomy.11 22
Implications for clinical practice
In women at high risk of developing breast cancer, there
has been an increase in BM since the publication of
NICE guidance (2004 and 2006).1 In an otherwise
healthy woman, BM is a radical approach to risk reduc-
tion, but has been estimated to reduce the incidence of
breast cancer in BRCA carriers by up to 90%.3 NICE
emphasises the importance of patient-led decision-
making and provides detailed recommendations regard-
ing the need for a specialist multidisciplinary approach
Figure 1 Sample of women included in the study.
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that includes psychological counselling, with clear infor-
mation provided on the extent of risk reduction and the
options for breast reconstruction.
The high rate of immediate breast reconstruction after
BM among women without breast cancer suggests that
reconstruction is widely available for these patients. This
seems appropriate as women who undergo breast recon-
struction report higher levels of satisfaction with their
postsurgery appearance than women who undergo mast-
ectomy alone.22
In women with a personal history or new diagnosis of
unilateral breast cancer the value of contralateral mast-
ectomy for risk reduction is more controversial. For this
group of women, decision-making is complicated. It is
likely that the risk of dying or the need for further
cancer treatment is determined primarily by the biology
and stage of the index cancer, rather than by a subse-
quent cancer in the contralateral breast.5 The risk of
subsequent cancers is likely to be reduced by the treat-
ment of the index cancer 24 and any future cancers are
likely to be surveillance-detected with a correspondingly
better prognosis.25 Consequently, a risk-reducing contra-
lateral mastectomy may not confer any beneﬁt. Some
women may still prefer to have a contralateral mastec-
tomy to avoid the stress of long-term regular surveillance
and risk of a subsequent cancer and related treatment.
CONCLUSION
Over the past decade, the number of women having a
bilateral mastectomy in England has increased. The
increase was proportionately greater in women without
breast cancer and within this group, 90% have breast
reconstruction at the time of their bilateral mastectomy.
However, the majority of women who undergo bilateral
mastectomy appear to have had unilateral breast cancer.
The evidence to support contralateral risk reducing
mastectomy in women with breast cancer is limited.
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